hero image

Biogen Reports First Quarter 2021 Results

April 22, 2021 Investor Relations
thumb
April 28, 2021
Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its supplemental Biologic License Application (sBLA) for a new subcutaneous (SC) route of

Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics
April 28, 2021
Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics

Accelerated action on climate, health and equity, including new plastic-free packaging goals for finished goods by 2025 1 Disclosed 2020 global pay equity analysis results 2 and launched enhanced four-part diversity, equity and inclusion strategy Tied a portion of employees’ and executive officers’